Perceptive Xontogeny Venture Fund

Perceptive Xontogeny Venture Fund is a venture capital fund focusing on early-stage life sciences companies. The fund primarily invests in companies seeking lead investors for Series A financings, including those seeded and incubated by Xontogeny and other organizations. It also participates in syndicated Series A financings as a co-lead or passive investor with other venture capital firms. The fund's strategy emphasizes advancing technologies from preclinical stages through early clinical development and generating proof-of-concept data in patients. The fund's portfolio includes investments across various modalities and therapeutic areas, with a greater emphasis on drug technologies and a lesser focus on early drug and discovery platforms. The fund's goal is to apply a more capital-efficient model of early drug development by actively managing a select number of the best opportunities with a focus on a successful and expedited path to compelling clinical proof-of-concept data. The fund is led by Chris Garabedian, Portfolio Manager, who also serves as Chairman and CEO of Xontogeny. The fund has closed two funds to date: the inaugural fund in 2019 with $210 million in commitments and the second fund in 2021 with $515 million in commitments. The fund's investments include companies such as Peroxitech, AsclepiX Therapeutics, Forge Biologics, and Adaptilens. The fund's investment approach includes active management via lead or co-lead Series A and select growth-stage financings, with investments ranging from $10-50 million, providing support as a syndicate investor in larger early-stage financings, and a data-driven approach focusing on advancing technologies from preclinical stage through clinical proof-of-concept. The fund's experienced team brings operational experience to Board of Director roles. The fund's sectors include biotechnology, medtech (medical devices and diagnostics), healthtech, digital health, and healthcare tools/services. The fund's investment interests include biotechnology and non-therapeutics sub-sectors including, but not limited to: devices, diagnostics, digital health, and life sciences research and healthcare information technology. The fund's recent investments include Series A lead investments in March 2020, June 2020, July 2020, and April 2024, and Series B syndicate investment in December 2022. The fund's portfolio companies include Peroxitech, AsclepiX Therapeutics, Forge Biologics, and Adaptilens. The fund's investment requirements include a focus on early-stage life sciences companies seeking lead investors for Series A financings, with a preference for companies seeded and incubated by Xontogeny and other organizations, and an openness to participating in syndicated Series A financings as a co-lead or passive investor with other venture capital firms. The fund's year founded is 2018. The fund's portfolio companies include Peroxitech, AsclepiX Therapeutics, Forge Biologics, and Adaptilens.